FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1950989874> ?p ?o ?g. }

• W1950989874 endingPage "iv66" @default.
• W1950989874 startingPage "iv66" @default.
• W1950989874 abstract "ABSTRACT Aim: In the last decade, we have witnessed a revolution in the molecular genetics of NSCLC (Non Small Cell Lung Cancer). These advances have led to the development of a multitude of prognostic and predictive biomarkers. Somatic mutations in EGFR (Epidermal Growth Factor Receptor) gene & ALK (Anaplastic Lymphoma Kinase) translocation are two “actionable” biomarkers that have passed clinical validation and are incorporated into current treatment paradigms. This abstract contributes towards understanding the epidemiology of ALK mutation in NSCLC patients in India. Methods: This was an observational study within the cohort of NSCLC patients. Pfizer Ltd supported this study as a part of Diagnostic Assistance Program. A total of 3351 patients of lung adenocarcinoma were tested from Jan 2013 to Mar 2014. These samples were collected from various locations across the country. ALK mutation was studied using the FDA approved Vysis ALK Gene Breakapart Probe Kit and the EGFR mutation testing (exons 18-21) was done using PCR followed by bidirectional Sanger's Sequencing. Results: Of the 3351 samples tested, 2146 (64.04%) were male & 1205 (35.96%) were females. Patients ranged in age from 25-90yrs with a median age of 57.94yrs. Biomarker testing for EGFR and ALK was performed on FFPE specimen of patients with confirmed adenocarcinoma histology. ALK testing was performed on 3351 samples and EGFR analysis on 3079. Of samples received for EGFR, 2653 (86.16%) were successfully analyzed & reported, 177 (5.75%) showed unsatisfactory results, and test could not be performed in 249 cases (8.09%). 2810 (83.86%) samples received for ALK testing by FISH could be successfully reported, 287 (8.56%) showed unsatisfactory results and 254 samples (7.58%) could not be tested. Common reasons for unsatisfactory results were presence of high degree of necrosis, scanty tumor or suboptimal fixation. Of the successfully reported cases, 28.19% were positive for presence of EGFR mutations. Mutations were observed in exon 18 (2.27%), exon 19 (72.99%), exon 20 (3.48%) and exon 21 (21.26%). 71 (2.53%) of the 2810 successfully reported cases were found Positive for ALK Gene Rearrangement. None of the samples showed a concomitant mutation. Conclusions: This study on 3351 adenocarcinoma enriched NSCLC patients of Indian origin, shows an ALK positivity of 2.53% & EGFR mutation positivity of 28.19%. Disclosure: All authors declare that he study was funded by Pfizer Ltd as a part of its Diagnostic Assistance Program. Other than that there is no disclosure to declare." @default.
• W1950989874 created "2016-06-24" @default.
• W1950989874 creator A5000398006 @default.
• W1950989874 creator A5005049404 @default.
• W1950989874 creator A5011569185 @default.
• W1950989874 creator A5027291775 @default.
• W1950989874 creator A5035846372 @default.
• W1950989874 creator A5040695549 @default.
• W1950989874 creator A5044799442 @default.
• W1950989874 creator A5051407707 @default.
• W1950989874 creator A5055220224 @default.
• W1950989874 creator A5056234705 @default.
• W1950989874 creator A5059703821 @default.
• W1950989874 creator A5070631722 @default.
• W1950989874 creator A5081498212 @default.
• W1950989874 date "2014-09-01" @default.
• W1950989874 modified "2023-09-27" @default.
• W1950989874 title "Experience of Alk Mutation Testing in 3351 Indian Patients of Nsclc" @default.
• W1950989874 doi "https://doi.org/10.1093/annonc/mdu326.25" @default.
• W1950989874 hasPublicationYear "2014" @default.
• W1950989874 type Work @default.
• W1950989874 sameAs 1950989874 @default.
• W1950989874 citedByCount "0" @default.
• W1950989874 crossrefType "journal-article" @default.
• W1950989874 hasAuthorship W1950989874A5000398006 @default.
• W1950989874 hasAuthorship W1950989874A5005049404 @default.
• W1950989874 hasAuthorship W1950989874A5011569185 @default.
• W1950989874 hasAuthorship W1950989874A5027291775 @default.
• W1950989874 hasAuthorship W1950989874A5035846372 @default.
• W1950989874 hasAuthorship W1950989874A5040695549 @default.
• W1950989874 hasAuthorship W1950989874A5044799442 @default.
• W1950989874 hasAuthorship W1950989874A5051407707 @default.
• W1950989874 hasAuthorship W1950989874A5055220224 @default.
• W1950989874 hasAuthorship W1950989874A5056234705 @default.
• W1950989874 hasAuthorship W1950989874A5059703821 @default.
• W1950989874 hasAuthorship W1950989874A5070631722 @default.
• W1950989874 hasAuthorship W1950989874A5081498212 @default.
• W1950989874 hasConcept C104317684 @default.
• W1950989874 hasConcept C117643217 @default.
• W1950989874 hasConcept C121608353 @default.
• W1950989874 hasConcept C126322002 @default.
• W1950989874 hasConcept C143998085 @default.
• W1950989874 hasConcept C2776232967 @default.
• W1950989874 hasConcept C2776256026 @default.
• W1950989874 hasConcept C2781182431 @default.
• W1950989874 hasConcept C2781197716 @default.
• W1950989874 hasConcept C501734568 @default.
• W1950989874 hasConcept C54355233 @default.
• W1950989874 hasConcept C71924100 @default.
• W1950989874 hasConcept C76818968 @default.
• W1950989874 hasConcept C86803240 @default.
• W1950989874 hasConceptScore W1950989874C104317684 @default.
• W1950989874 hasConceptScore W1950989874C117643217 @default.
• W1950989874 hasConceptScore W1950989874C121608353 @default.
• W1950989874 hasConceptScore W1950989874C126322002 @default.
• W1950989874 hasConceptScore W1950989874C143998085 @default.
• W1950989874 hasConceptScore W1950989874C2776232967 @default.
• W1950989874 hasConceptScore W1950989874C2776256026 @default.
• W1950989874 hasConceptScore W1950989874C2781182431 @default.
• W1950989874 hasConceptScore W1950989874C2781197716 @default.
• W1950989874 hasConceptScore W1950989874C501734568 @default.
• W1950989874 hasConceptScore W1950989874C54355233 @default.
• W1950989874 hasConceptScore W1950989874C71924100 @default.
• W1950989874 hasConceptScore W1950989874C76818968 @default.
• W1950989874 hasConceptScore W1950989874C86803240 @default.
• W1950989874 hasLocation W19509898741 @default.
• W1950989874 hasOpenAccess W1950989874 @default.
• W1950989874 hasPrimaryLocation W19509898741 @default.
• W1950989874 hasRelatedWork W1506244879 @default.
• W1950989874 hasRelatedWork W1967738163 @default.
• W1950989874 hasRelatedWork W2009775937 @default.
• W1950989874 hasRelatedWork W2049195720 @default.
• W1950989874 hasRelatedWork W2096458472 @default.
• W1950989874 hasRelatedWork W2168484036 @default.
• W1950989874 hasRelatedWork W2327571925 @default.
• W1950989874 hasRelatedWork W2366378543 @default.
• W1950989874 hasRelatedWork W2549079293 @default.
• W1950989874 hasRelatedWork W2582530536 @default.
• W1950989874 hasRelatedWork W2740913802 @default.
• W1950989874 hasRelatedWork W2768548286 @default.
• W1950989874 hasRelatedWork W2781872788 @default.
• W1950989874 hasRelatedWork W2898248948 @default.
• W1950989874 hasRelatedWork W2901521863 @default.
• W1950989874 hasRelatedWork W2947181236 @default.
• W1950989874 hasRelatedWork W2949424504 @default.
• W1950989874 hasRelatedWork W3000138981 @default.
• W1950989874 hasRelatedWork W3008564975 @default.
• W1950989874 hasRelatedWork W3029259409 @default.
• W1950989874 hasVolume "25" @default.
• W1950989874 isParatext "false" @default.
• W1950989874 isRetracted "false" @default.
• W1950989874 magId "1950989874" @default.
• W1950989874 workType "article" @default.